--A U.S. jury decision that said Amgen Inc.'s (AMGN) Repatha patents were valid has been mostly set aside by a judge, Reuters reported Wednesday.

--In February, a Delaware jury verdict upheld two Amgen patents related to PCSK9 antibodies.

--Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) contended Amgen's patent claims to the antibodies were overly broad.

--In February, the two companies said they planned to file post-trial motions in an effort to overturn the verdict and request a new trial, and would, if necessary, file an appeal with the U.S. Court of Appeals for the Federal Circuit.

Full story: https://www.reuters.com/article/us-amgen-sanofi-patent/u-s-judge-rules-for-sanofi-in-amgen-patent-fight-idUSKCN1VI2E9

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

August 28, 2019 16:23 ET (20:23 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Amgen Charts.